Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Erika Hamilton, The Director of Breast Cancer Program at Sarah Cannon Research Institute, shared on X about recent paper by Komal L. Jhaveri et al., titled “Imlunestrant with or without Abemaciclib in Advanced Breast Cancer” published on The New England Journal of Medicine.
Authors: Komal L. Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O’Shaughnessy, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, Antonio Llombart-Cussac, Elgene Lim, María de la Luz García Tinoco, Joohyuk Sohn, André Mattar, Qingyuan Zhang, Chiun-Sheng Huang, Chih-Chiang Hung, Jorge Luis Martinez Rodriguez, Manuel Ruíz Borrego, Rikiya Nakamura, Kamnesh R. Pradhan, Christoph Cramer von Laue, Emily Barrett, Shanshan Cao, Xuejing Aimee Wang, Lillian M. Smyth, François-Clément Bidard
“Imlunestrant with or without abema out in The New England Journal of Medicine this morning.
- Imlunestrant alone beneficial in only ESR1 subgroup.
- With abema, benefits all.”
Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023